Navigation Links
DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
Date:5/3/2012

tive drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER®, ORADUR®, TRANSDUR® and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR, TRANSDUR-Sufentanil and Relday are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement The statements in this press release regarding the potential bioavailability studies for REMOXY, potential regulatory meetings and submissions for REMOXY and POSIDUR, anticipated clinical trials (including timing and results) for Relday and our other drug candidates, the potential benefits and uses of our drug candidates, collaborations with third parties and potential business development activities are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including rejection of meeting requests, requests for additional information or product non-approval, delays and additional costs due to requirements imposed by regulatory agencies, potential adverse effects arising from the testing or use of our drug candidates, the potential failure of our clinical trials to meet
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
2. DURECT Corporation Invites You to Join Its Fourth Quarter 2011 Earnings Conference Call
3. DURECT to Participate in Upcoming Healthcare Conferences
4. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
5. DURECT Corporation Invites You to Join its Third Quarter 2011 Earnings Conference Call
6. DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
7. DURECT Corporation to Participate in Upcoming Healthcare Conferences
8. DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
9. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
10. DURECT to Present at the Jefferies Healthcare Conference
11. DURECT Announces Resignation of Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
(Date:10/20/2014)... Norgine B.V. today announced that ... bowel preparation, NER1006, presented at the 79 th ... (ACG), Philadelphia, PA , has met ... co-primary endpoint of cleansing success. The study demonstrated high ... in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... FRANKFURT , Deutschland, October 19, 2014 /PRNewswire/ ... echten CRT-Fallstudien gefragt. Das Problem dabei ... ihre Informationen mit der Kompetenz zu teilen. ... zusammenzustellen, und deshalb freuen wir uns umso mehr, ... Pharmafirmen gebeten, ihre Gepflogenheiten bei Kühlketten aufzuschreiben - ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... Arthritis Foundation,the leading health organization addressing the needs ... that Amgen and Wyeth,Pharmaceuticals, co-marketers of Enbrel (R) ... 2008 Arthritis Walk (R)., "The Arthritis Foundation ... funds to prevent, control and cure arthritis, the,nation,s ...
... in, Achieving Red Blood Cell Transfusion Independence, Hematologic Improvement ... ... the 49th American Society of Hematology (ASH) Meeting, ATLANTA, ... interim data from a Phase 2 clinical trial,evaluating three alternative ...
Cached Medicine Technology:Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 2Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 3Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 4MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 2MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 3MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 4MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 5MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 6
(Date:10/20/2014)... It’s hard to imagine what it’s like to ... around the world, it’s a reality. And while new shoes ... forced to walk barefoot on rocky terrain or sewage-lined streets ... their friends. , Buckner International's Shoes for Orphan ... in October to encourage support for Air1 and while also ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
(Date:10/19/2014)... 20, 2014 Having been working in the ... knowledge of customer needs. According to James, one of the ... dazzling sequins, or with high-low skirts that add beauty to ... demand. Recently, LunaDress has unveiled its new selection of 2014 ... the company’s brand new items are available in over 20 ...
(Date:10/19/2014)... a professional company of women’s dresses and related accessories, ... dresses . All the company’s old and new client ... up to 66 percent off. , SweetDressy.com is ... Its dress specialists are striving to make more trendy ... world. All the company’s items are unique, graceful and ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... earlier U.S. study had different conclusion , THURSDAY, April ... being treated for erectile dysfunction finds an association between ... of the male hormone testosterone. , The study "sends ... director of sexual medicine at Alvarado Hospital in San ...
... plateaus, says CDC report , THURSDAY, April 15 (HealthDay ... food-related illnesses caused by several common bacteria, including the most ... a pathogen most often acquired from oysters which can cause ... rates of Salmonella infection have remained flat in recent years. ...
... conducted by a collaborative team led by researchers from the ... into the clinical outcome for some patients with a particularly ... a framework for development of targeted drug treatments. The ... in the journal Cancer Cell, used epigenomics to ...
... baby boomers will benefit from Social Security and Medicare at ... government-run programs will pay out more than they collect in ... from the University of California, Berkeley, concludes that younger Americans ... actually getting the better deal when the value of public ...
... ... Solution Enhances Tracking and Management of Items, Assets, and Containers, , ... (PRWEB) April 15, 2010 -- ... Frequency Identification (RFID) solutions, today announced that they are partnering to offer the industry,s ...
... ... to announce that Maureen Hanrahan has joined the company as a senior consultant specializing ... Medicaid and SCHIP. , ... (PRWEB) April 15, 2010 -- ArpegioHealth is pleased to announce that ...
Cached Medicine News:Health News:Do Statins Lower Male Sex Drive? 2Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 2Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 3Health News:USC researchers discover new molecular subtype of brain cancer 2Health News:For post-boomers, public education worth more than Social Security and Medicare 2Health News:For post-boomers, public education worth more than Social Security and Medicare 3Health News:Savi and ODIN to Deliver Industry's Most Comprehensive RFID Software Platform 2Health News:Savi and ODIN to Deliver Industry's Most Comprehensive RFID Software Platform 3Health News:Hanrahan Joins ArpegioHealth Consulting Firm 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... immunosorbent assay method for the semi-quantitative ... myeloperoxidase in human serum. The results ... used as an aid in the ... conditions associated with elevated anti-neutrophil cytoplasmic ...
... Ang II is a helpful ... effect and efficiency of a ... enzyme inhibitors (ACE Inhibitors) or ... well as for the efficiency ...
Medicine Products: